Therapeutic Asset Ratings

91,564 assets · 7,904 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Atogepant Migraine Disorder	Stanford University	P4	A (87)
Firazyr Hereditary Angioedema	Nang Kuang Pharmaceutical Co., Ltd.	P4	A (87)
Tafamidis Familial Amyloid Neuropathy	Qilu Pharmaceutical Co., Ltd.	P4	A (87)
Idursulfase Mucopolysaccharidosis Type 2	Takeda	P4	A (86)
Turoctocog Alfa Inherited Blood Coagulation Disorder	Novo Nordisk A/S	P4	A (85)
Turoctocog Alfa Hemophilia A	Novo Nordisk A/S	P4	A (85)
eptacog alfa (activated) Hemophilia A	AryoGen Pharmed Co.	P4	A (84)
Factor Ix Hemophilia B	CSL Behring	P4	A (84)
Gly-Gly-Gly-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-Nh2 (4-9 Disulfide) Hepatorenal Syndrome	Noorik Biopharmaceuticals AG	P4	A (84)
Recombinant Alpha-Galactosidase A Fabry Disease	Shire	P4	A (84)
Sebetralstat Hereditary Angioedema	KalVista Pharmaceuticals, Ltd.	P4	A (84)
Velpatasvir Hepatitis C Virus Infection	Peking University People's Hospital	P4	A (84)
Agalsidase Beta Fabry Disease	Sanofi	P4	A (83)
.ALPHA.-D-GLUCOSYL-N-ACYLSPHINGOSINE GLUCOHYDROLASE Gaucher Disease Type I	Sanofi	P4	A (83)
Aspirin Myocardial Infarction	Shanghai CureGene Pharmaceutical Co., Ltd.	P4	A (83)
ATORVASTATIN Inherited Lipid Metabolism Disorder	Johns Hopkins University	P4	A (83)
Edoxaban Atrial Fibrillation	National Taiwan University Hospital	P4	A (83)
Nicotine Nicotine Dependence	Brown University	P4	A (83)
Velaglucerase Alfa Gaucher Disease	Takeda	P4	A (83)
VITAMIN D Vitamin D Deficiency	Yale University	P4	A (83)
Alpha-1-Proteinase Inhibitor Alpha 1-Antitrypsin Deficiency	Grifols Therapeutics LLC	P4	A (82)
Brexpiprazole Depressive Disorder	Dr. Albert Kar-Kin Chung	P4	A (82)
Cytarabine Acute Promyelocytic Leukemia	Associazione Italiana Ematologia Oncologia Pediatrica	P4	A (82)
Dexasone Chemotherapy-Induced Toxicity	Instituto do Cancer do Estado de São Paulo	P4	A (82)
Lurasidone Bipolar Depression	NeuroRx, Inc.	P4	A (82)

Showing 1 to 25 of 42,327 assets

PreviousPage 1 of 1694Next